MeSH term
Frequency | Condition_Probility | Adult | 57 | 0.0 |
Aged | 28 | 0.0 |
Female | 62 | 0.0 |
Humans | 235 | 0.0 |
Male | 59 | 0.0 |
Middle Aged | 48 | 0.0 |
Prospective Studies | 5 | 0.0 |
Amino Acid Sequence | 36 | 0.0 |
Anti-HIV Agents/*pharmacology | 3 | 2.0 |
Antigens, CD4/*metabolism/pharmacology | 2 | 66.0 |
Cell Line, Transformed | 7 | 0.0 |
Drug Synergism | 4 | 0.0 |
HIV Envelope Protein gp120/metabolism | 11 | 7.0 |
HIV Envelope Protein gp41/chemistry/*metabolism | 2 | 33.0 |
HIV-1/*drug effects/metabolism | 2 | 14.0 |
Molecular Sequence Data | 46 | 0.0 |
Research Support, Non-U.S. Gov't | 134 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 80 | 0.0 |
Solubility | 66 | 4.0 |
Antigens, CD4/*blood/chemistry | 2 | 100.0 |
Osmolar Concentration | 3 | 0.0 |
Recurrence | 3 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Antigens, CD4/*chemistry/genetics/*metabolism | 2 | 22.0 |
Binding Sites | 17 | 0.0 |
Glycosylation | 6 | 0.0 |
In Vitro | 14 | 0.0 |
Models, Molecular | 8 | 0.0 |
Protein Binding | 15 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 19 | 1.0 |
Cells, Cultured | 21 | 0.0 |
Chromatography, Gel | 4 | 0.0 |
Coculture Techniques | 2 | 0.0 |
HIV Envelope Protein gp120/immunology | 3 | 3.0 |
Neutralization Tests | 38 | 8.0 |
Case-Control Studies | 5 | 0.0 |
Lymphocytes/immunology | 3 | 0.0 |
Polymerase Chain Reaction | 8 | 0.0 |
Antigens, CD4/physiology | 3 | 3.0 |
Cell Line | 56 | 0.0 |
Cross Reactions/*immunology | 2 | 20.0 |
Epitopes/chemistry/genetics/immunology | 2 | 20.0 |
HIV Antibodies/*immunology | 14 | 14.0 |
*Neutralization Tests | 2 | 33.0 |
Phenotype | 6 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 14 | 0.0 |
Antigens, CD4/metabolism | 11 | 3.0 |
*Cell Fusion | 2 | 5.0 |
HIV/*immunology | 3 | 2.0 |
HIV Envelope Protein gp120/*immunology/metabolism | 3 | 25.0 |
Receptors, CXCR4/metabolism | 2 | 1.0 |
Cerebrospinal Fluid/cytology | 3 | 12.0 |
English Abstract | 7 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
*Antibody Specificity | 2 | 2.0 |
HIV-1/*immunology | 20 | 4.0 |
Animals | 54 | 0.0 |
CHO Cells | 8 | 0.0 |
Hamsters | 14 | 0.0 |
Immunoglobulins, Fab/immunology | 3 | 2.0 |
Antigens, CD4/*physiology | 5 | 4.0 |
Gene Products, env/metabolism | 3 | 5.0 |
HIV Envelope Protein gp120/*metabolism | 24 | 15.0 |
HIV Envelope Protein gp41/*metabolism | 4 | 22.0 |
Viral Fusion Proteins/*metabolism | 2 | 16.0 |
Antigens, CD4/blood | 17 | 28.0 |
Antigens, CD8/*blood | 19 | 61.0 |
Comparative Study | 22 | 0.0 |
Receptors, Interleukin-2/analysis | 11 | 4.0 |
T-Lymphocyte Subsets/immunology | 9 | 2.0 |
Antigens, CD4/*chemistry/metabolism | 3 | 21.0 |
Virus Replication | 10 | 1.0 |
Antigens, CD4/*metabolism | 26 | 8.0 |
Base Sequence | 16 | 0.0 |
Binding Sites/physiology | 2 | 1.0 |
Chromatography, Affinity | 3 | 0.0 |
*Enzyme-Linked Immunosorbent Assay | 2 | 2.0 |
Epitopes/metabolism | 3 | 5.0 |
HIV-1/*metabolism | 18 | 7.0 |
Peptide Fragments/*metabolism | 3 | 2.0 |
Peptide Library | 2 | 1.0 |
Antigens, CD8/blood | 14 | 35.0 |
Cytokines/blood | 3 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Viral Load | 2 | 0.0 |
Antigens, CD4/*analysis/immunology | 2 | 22.0 |
Blotting, Western | 3 | 0.0 |
CD8-Positive T-Lymphocytes/immunology | 5 | 1.0 |
Disease Progression | 2 | 0.0 |
Severity of Illness Index | 4 | 0.0 |
Antigens, CD4/chemistry/*metabolism | 9 | 33.0 |
Biosensing Techniques | 3 | 5.0 |
HIV-1/genetics/*metabolism | 2 | 2.0 |
Kinetics | 22 | 0.0 |
Protein Binding/genetics | 2 | 0.0 |
Protein Conformation | 19 | 0.0 |
Receptors, CCR5/*metabolism | 4 | 2.0 |
Sequence Deletion | 4 | 0.0 |
Transfection | 11 | 0.0 |
Antigens, CD4/immunology | 9 | 4.0 |
Gene Products, env/immunology | 3 | 10.0 |
Interferon Type II/blood | 3 | 2.0 |
Mice | 17 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Antigens, CD4/immunology/*metabolism | 5 | 17.0 |
*Bacterial Proteins | 3 | 1.0 |
Carrier Proteins/*pharmacology | 3 | 6.0 |
Flow Cytometry | 17 | 0.0 |
HIV Envelope Protein gp120/drug effects/*metabolism | 3 | 60.0 |
Precipitin Tests | 4 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Adolescent | 15 | 0.0 |
Child | 9 | 0.0 |
Child, Preschool | 9 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
HIV Antibodies/immunology | 5 | 8.0 |
HIV Envelope Protein gp120/genetics/*immunology | 2 | 10.0 |
Immunophenotyping | 5 | 0.0 |
DNA, Viral/analysis | 2 | 0.0 |
*Gene Therapy | 2 | 0.0 |
HIV Envelope Protein gp41/*immunology | 3 | 14.0 |
Transduction, Genetic | 2 | 0.0 |
Antigens, CD/blood | 3 | 1.0 |
Combined Modality Therapy | 3 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Prognosis | 2 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Tumor Markers, Biological/*blood | 3 | 0.0 |
beta 2-Microglobulin/analysis | 2 | 1.0 |
Aged, 80 and over | 7 | 0.0 |
Antigens, CD8/*metabolism | 3 | 9.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Lymphocyte Activation/immunology | 4 | 0.0 |
T-Lymphocytes/immunology | 7 | 0.0 |
Hela Cells | 9 | 0.0 |
Membrane Fusion | 5 | 3.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Cytokines/*blood | 8 | 2.0 |
Danazol/*therapeutic use | 2 | 18.0 |
Follow-Up Studies | 2 | 0.0 |
Interleukin-6/blood | 4 | 0.0 |
Tumor Necrosis Factor-alpha/analysis | 5 | 1.0 |
Binding Sites, Antibody | 4 | 1.0 |
Macromolecular Substances | 3 | 0.0 |
Protein Denaturation | 2 | 0.0 |
Thermodynamics | 3 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Antiviral Agents/*pharmacology | 4 | 2.0 |
Cats | 2 | 0.0 |
HIV-1/*drug effects | 4 | 2.0 |
Membrane Fusion/drug effects | 2 | 6.0 |
Viral Envelope Proteins/*metabolism | 3 | 6.0 |
Leukocyte Count | 7 | 0.0 |
Lymphocyte Activation/*immunology | 3 | 0.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
T-Lymphocytes/*immunology | 13 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Ligands | 6 | 0.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Epitopes/immunology | 7 | 1.0 |
Membrane Fusion/*physiology | 2 | 7.0 |
Autoantibodies/analysis | 2 | 1.0 |
*Lymphocyte Activation | 6 | 0.0 |
Receptors, Interleukin-2/blood | 5 | 6.0 |
T-Lymphocytes/drug effects/*immunology | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
HIV Envelope Protein gp120/chemistry/*metabolism | 4 | 30.0 |
Cricetulus | 4 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Temperature | 9 | 0.0 |
Antigens, CD4/chemistry/metabolism/*pharmacology | 2 | 100.0 |
HIV Envelope Protein gp120/genetics/immunology/*metabolism | 2 | 33.0 |
*HIV-1 | 5 | 0.0 |
CD4-Positive T-Lymphocytes/*virology | 2 | 2.0 |
*Membrane Glycoproteins | 2 | 0.0 |
*Viral Envelope Proteins | 2 | 4.0 |
Antigens, CD4/*blood | 18 | 40.0 |
Biological Markers/blood | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 29 | 0.0 |
Intercellular Adhesion Molecule-1/*blood | 3 | 5.0 |
Receptors, Interleukin-2/*blood | 4 | 7.0 |
Tacrolimus/therapeutic use | 2 | 28.0 |
Antigens, CD4/*immunology | 21 | 6.0 |
Cross-Linking Reagents | 6 | 1.0 |
Antigens, Neoplasm/*blood | 2 | 4.0 |
Psoriasis/*immunology | 2 | 11.0 |
beta 2-Microglobulin/*metabolism | 3 | 7.0 |
Biological Markers | 6 | 0.0 |
Cytokines/*immunology | 2 | 2.0 |
HIV Envelope Protein gp120/*immunology | 14 | 11.0 |
HIV-1/*immunology/isolation & purification | 4 | 14.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Pregnancy | 4 | 0.0 |
Receptors, Interleukin-2/blood/metabolism | 2 | 100.0 |
Acute Disease | 9 | 0.0 |
Antigens, CD/*blood | 2 | 1.0 |
CD4 Lymphocyte Count | 2 | 0.0 |
Convalescence | 2 | 6.0 |
Time Factors | 4 | 0.0 |
Antigens, CD4/analysis | 5 | 1.0 |
Immunoenzyme Techniques | 2 | 0.0 |
COS Cells | 2 | 0.0 |
HIV Envelope Protein gp120/*immunology/physiology | 2 | 100.0 |
Recombinant Proteins/immunology | 10 | 2.0 |
HIV-1/*physiology | 6 | 1.0 |
*Protein Conformation | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/*virology | 2 | 10.0 |
Histocompatibility Antigens Class I/blood | 2 | 25.0 |
beta 2-Microglobulin/metabolism | 3 | 3.0 |
Antibody Specificity | 6 | 0.0 |
Liver Diseases/immunology | 2 | 13.0 |
CD4-Positive T-Lymphocytes/immunology | 6 | 0.0 |
HIV Infections/*metabolism | 2 | 4.0 |
Dimerization | 2 | 0.0 |
HIV/immunology | 2 | 3.0 |
Mutagenesis | 3 | 0.0 |
Antigens, CD4/*analysis | 11 | 6.0 |
Antigens, CD8/*analysis | 10 | 14.0 |
Immunity, Cellular | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*analysis | 2 | 0.0 |
Receptors, CXCR4 | 2 | 5.0 |
HIV Infections/*immunology | 6 | 1.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
Immunoglobulin M/analysis | 2 | 0.0 |
Virus Replication/*drug effects | 3 | 1.0 |
Mutation | 2 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Remission Induction | 2 | 0.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Intercellular Adhesion Molecule-1/blood | 3 | 3.0 |
Lymphocyte Activation | 12 | 0.0 |
Computer Simulation | 2 | 0.0 |
Drug Design | 2 | 0.0 |
HIV Envelope Protein gp120/*chemistry/immunology | 2 | 40.0 |
CD4-CD8 Ratio | 5 | 0.0 |
Lymphocyte Count | 3 | 0.0 |
T-Lymphocyte Subsets | 2 | 1.0 |
Antibodies, Monoclonal | 10 | 0.0 |
CD4-Positive T-Lymphocytes/*metabolism | 2 | 2.0 |
Biological Markers/*blood | 2 | 1.0 |
Prednisolone/therapeutic use | 3 | 3.0 |
Epitopes/*immunology | 3 | 1.0 |
HIV Envelope Protein gp41/immunology | 2 | 9.0 |
Immunotoxins/*pharmacology | 4 | 9.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
HIV Antigens/*immunology | 4 | 7.0 |
HIV-1/immunology/*metabolism | 2 | 20.0 |
Virion/immunology/*metabolism | 2 | 40.0 |
HIV Envelope Protein gp120/*physiology | 2 | 6.0 |
Antigens, CD4/pharmacology | 2 | 28.0 |
HIV Envelope Protein gp120/chemistry/*immunology | 2 | 14.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Recombinant Proteins/pharmacology | 5 | 0.0 |
Neopterin | 3 | 3.0 |
Antigens, CD4/*cerebrospinal fluid | 3 | 100.0 |
Leukemia, T-Cell/*cerebrospinal fluid/pathology | 2 | 100.0 |
Receptors, Interleukin-2/*analysis | 8 | 11.0 |
Cercopithecus aethiops | 2 | 0.0 |
Genes, env | 2 | 3.0 |
Models, Structural | 2 | 1.0 |
Sequence Alignment | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Antibodies, Viral | 2 | 8.0 |
HIV Envelope Protein gp120/*genetics | 2 | 8.0 |
Immune Sera | 2 | 0.0 |
Recombinant Proteins | 6 | 0.0 |
Serial Passage | 2 | 12.0 |
HIV Envelope Protein gp120/*genetics/metabolism | 3 | 23.0 |
Protein Precursors/metabolism | 2 | 1.0 |
HIV Envelope Protein gp120/immunology/*metabolism | 3 | 15.0 |
Mice, Inbred C3H | 2 | 0.0 |
CD4 Immunoadhesins/*pharmacology | 2 | 50.0 |
Rabbits | 3 | 0.0 |
Lymphocytes | 3 | 1.0 |
RNA-Directed DNA Polymerase/metabolism | 2 | 2.0 |
Infectious Mononucleosis/*immunology | 2 | 10.0 |
Giant Cells | 3 | 5.0 |
Antigens, CD8/analysis | 4 | 1.0 |
Antigens, CD4/*pharmacology | 5 | 50.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
Cell Fusion | 2 | 0.0 |
HIV-1/immunology/*pathogenicity | 2 | 14.0 |
Cross Reactions | 2 | 0.0 |
Immunoassay | 2 | 0.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
Lymphocytes/*immunology | 2 | 0.0 |
Blood Sedimentation | 2 | 1.0 |
Infant | 4 | 0.0 |
Antibodies, Monoclonal/metabolism | 4 | 1.0 |
Dextran Sulfate/pharmacology | 2 | 11.0 |
Macrophages/*microbiology | 2 | 6.0 |
T-Lymphocytes/*microbiology | 3 | 9.0 |
Dogs | 2 | 0.0 |
HIV Envelope Protein gp160 | 6 | 5.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 2 | 0.0 |
Binding, Competitive | 10 | 0.0 |
Immunoglobulin G/blood | 2 | 0.0 |
Receptors, Interleukin-2/*metabolism | 2 | 2.0 |
HIV Antibodies | 2 | 3.0 |
Vaccinia virus/genetics | 2 | 2.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
HIV Infections/*drug therapy | 2 | 0.0 |
Antigen-Antibody Reactions/*drug effects | 2 | 50.0 |
Recombinant Proteins/immunology/metabolism | 2 | 4.0 |
Peptide Fragments/*immunology | 2 | 1.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 3 | 1.0 |
Receptors, Interleukin-2/metabolism | 2 | 1.0 |
Cell Fusion/drug effects | 2 | 10.0 |
Epitopes | 3 | 0.0 |
HIV/*metabolism | 3 | 8.0 |
HIV Antibodies/metabolism | 2 | 28.0 |
HIV Envelope Protein gp41/metabolism | 6 | 24.0 |
HIV-1/metabolism | 2 | 4.0 |
Receptors, HIV/metabolism | 3 | 9.0 |
Receptors, Virus/*metabolism | 4 | 4.0 |
Antigens, CD/analysis | 2 | 0.0 |
Lymphocyte Activation/*drug effects | 3 | 0.0 |
HIV/*physiology | 3 | 4.0 |
Models, Biological | 2 | 0.0 |
T-Lymphocytes/*physiology | 2 | 0.0 |
Carbohydrate Conformation | 4 | 3.0 |
Carbohydrate Sequence | 4 | 1.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Rats | 4 | 0.0 |
Species Specificity | 2 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Gene Products, env/*metabolism | 2 | 7.0 |
HIV-1/*growth & development | 2 | 3.0 |
Synovial Fluid/immunology | 2 | 5.0 |
Antibodies, Antineutrophil Cytoplasmic | 2 | 4.0 |
Virus Replication/drug effects | 3 | 1.0 |
Glycopeptides/isolation & purification | 2 | 22.0 |
*ADP Ribose Transferases | 2 | 2.0 |
*Bacterial Toxins | 2 | 1.0 |
*Virulence Factors | 2 | 2.0 |
Immunoglobulins/blood | 2 | 2.0 |
Microscopy, Fluorescence | 2 | 0.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
*Antigens, CD4 | 3 | 12.0 |
Microscopy, Electron | 3 | 0.0 |
Virion/immunology | 3 | 17.0 |
HIV-2/*metabolism | 3 | 21.0 |
Viral Envelope Proteins/metabolism | 2 | 3.0 |
Autoantibodies/*immunology | 2 | 0.0 |
Immunoglobulin G/immunology | 3 | 0.0 |
Exotoxins/*pharmacology | 2 | 8.0 |
Recombinant Proteins/*pharmacology | 2 | 2.0 |
Antigen-Antibody Complex | 2 | 1.0 |
Antigens, CD4/*blood/metabolism | 2 | 100.0 |
Cell Fusion/physiology | 2 | 22.0 |
Cytopathogenic Effect, Viral | 2 | 1.0 |
Radioligand Assay | 2 | 0.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 2 | 0.0 |
Genetic Vectors | 4 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 2 | 0.0 |
HIV-1/immunology/*metabolism/physiology | 2 | 100.0 |
Structure-Activity Relationship | 4 | 0.0 |
Drosophila melanogaster | 2 | 1.0 |
T-Lymphocytes, Helper-Inducer/immunology | 2 | 1.0 |
Antigens, CD8 | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 3 | 2.0 |
Receptors, Antigen, T-Cell/metabolism | 2 | 1.0 |
Receptors, HIV | 4 | 7.0 |
T-Lymphocytes/microbiology | 2 | 8.0 |
Acquired Immunodeficiency Syndrome/*immunology | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/*blood | 2 | 4.0 |
Gene Products, env/*immunology | 2 | 8.0 |
Protein Precursors/*immunology | 2 | 13.0 |
Plasmids | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 4 | 0.0 |
Ovary | 2 | 4.0 |
HIV Seropositivity/immunology | 2 | 2.0 |
Peptide Fragments/isolation & purification | 2 | 3.0 |
Vaccines, Synthetic/immunology | 2 | 6.0 |
HIV Envelope Protein gp120 | 2 | 3.0 |
Retroviridae Proteins/metabolism | 2 | 15.0 |
Receptors, Antigen, T-Cell/*blood | 2 | 50.0 |
